Identification of novel EGFR inhibitors for glioblastoma through pharmacophore-guided virtual screening and molecular dynamics
The pharmacophore-based screening and docking analysis identified eleven promising EGFR-binding compounds, of which eight demonstrated optimal ADMET characteristics and stable interactions within the active site during molecular dynamics simulations, suggesting their potential efficacy as EGFR inhibitors.